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INTRODUCTION
In January 2015, the Asia-Pacific Hematology 
Consortium (APHCON) held sixth annual Bridging 
The Gap (BTG) conference series in Beijing, China 
where delegates participated in series of surveys using 
an innovative mobile education app called MDRingTM. 
Results of the module on acute myeloid leukemia (AML) 
[1] and that of multiple myeloma (MM) [2] were published 
independently. These took a first pass at revealing common 
standards of care and best practices, issues that remain 
controversial or debated, and educational or resource gaps 
that warrant attention. Here we present highlights from 
the other 11 surveys (Table 1), and provide complete set 
of questions and answers as Supplemental Material. This 
report serves as a snapshot of state-of-knowledge in Asia 
Pacific hematology oncology community, and establishes 
baseline for longitudinal investigations to follow changes 
in best practices over time. 
MATERIALS AND METHODS
Survey deployment and participation
We used the mobile application MDRingTM to 
conduct survey among delegates at the BTG 2015 Beijing 
conference. Survey consisted of 13 question and answer 
modules (Table 1). Average number of questions per 
module was 10, smallest included 2 questions, and the 
largest 25. Number of respondents ranged from 29 to 
105, with an average of 64 respondents per question. The 
average per module response rate ranged from a low-end 
outlier 66% to 94%, with an average of 86%. This level of 
engagement far exceeds the minimal expectation of 60%, 
typically cited as sufficient for reporting.
Data analysis
Data were initially analyzed as percentage of 
respondents selecting a particular answer. These values 
were calculated for the entire set of participants, and 
stratified based on national identity: China versus “Other”. 
We plotted every possible answer choice percentage 
for China versus Other and calculated coefficient of 
determination, or R2 value, as an overall assessment of 
agreement between geographic groups. For each question 
we used chi-squared analysis to determine whether 
observed answer choice percentages differed between 
geographies. We measured response concordance between 
geographic groups for each module in several ways. For 
each question we calculated R2, as above, as well as 
percent of multiple-choice answers selected in same rank 
order. We also determined range and mean difference in 
percent response for each answer choice, and the 95% 
confidence interval around that mean. Lastly, we grouped 
questions into five broad categories—diagnosis, stem 
cell transplant, general knowledge/opinion, patient info, 
and treatment preference—and estimated extent to which 
physicians agree with one another in each category. 
Degree of consensus is simply highest overall percent 
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among a given question’s multiple answer choices. That 
is, if choice A was selected by 75% of all respondents, 
maximum degree of consensus for that question was 
considered 75%. 
RESULTS AND DISCUSSION
Geographic stratification
Overall geographical concordance in survey 
responses was positive and strong (Figure 1a). Questions 
regarding molecular or cytological diagnostics generally 
received similar percentages of responses between groups. 
When multiple diagnostic factors can be considered, 
physicians report considering most if not all of relevant 
indicators. For example, module for aplastic anemia 
(AA) asks: “Which investigations are routinely used to 
make a diagnosis of AA?” Most physicians (nearly 70%) 
selected all available answer choices, and the proportions 
based on nationality were identical to their representation 
in survey (χ2 p-value = 0.93). To give another example, 
in myelodysplastic/myeloproliferative module, we 
asked: “Do you perform JAK2 mutation analysis in 
all myeloproliferative disease?” Overall response 
was 97% yes, 3% no, with both geographic groups 
represented proportionally. We can conclude that this 
diagnostic approach has almost reached saturation among 
practitioners in our sample set. The NCCN guidelines also 
recommend to perform molecular testing for JAK2 V617F 
mutations in patients with suspicion of myeloproliferative 
neoplasms. 
Perhaps more interesting than instances of absolute 
agreement, these data provide a unique opportunity to 
identify topics in which physician knowledge or opinions 
diverge. We assigned questions from all modules to 
broad categories of: patient info; diagnosis; treatment 
preference; transplantation; and general knowledge/
opinion. We found that questions pertaining to treatment 
preference (i.e. drug choice) yielded least unanimous 
responses, on average, whereas diagnosis questions 
elicited the most unanimous choices (Figure 1b). For 
instance, Non-Hodgkin Lymphoma (NHL) module asked: 
“What is your treatment of choice for salvage therapy 
for NHL?” Here, proportional representation was nearly 
identical between geographic groups, but physicians did 
not report same approach to care. Half of all respondents 
chose “combination chemotherapy,” while other half were 
divided among “rituximab-lenalidomide,” “Bortezomib-
lenalidomide-rituximab,” and “other.” Sheer number of 
questions with highly variable responses, especially in 
regards to treatment preference, indicates just how rarely 
we observed a single standard of care.
Examining geographic discrepancies also yielded 
an interesting perspective on what areas of treatment 
vary, and why. For example, chronic lymphocytic 
leukemia (CLL) module asked: “Your treatment of 
choice for relapsed/refractory CLL?” The majority of 
Chinese respondents selected Bendamustine (57%) with 
FCR second (38%). Meanwhile, 60% of the “Other” 
respondents chose Ibrutinib. Such a feedback is consistent 
with the existing NCCN guidelines where bendamustine 
+/- rituximab or reduced dose FCR are listed as options 
for relapsed/refractory CLL and Ibrutinib treatment is 
supported by category 1 level evidence.
Ibrutinib is a first-in-class non-chemotherapy 
tyrosine kinase inhibitor, but is not yet approved in 
Table 1: BTG2015 survey module participation.
Survey Module Number of questions Average response rate
Number of respondents / question
Overall China Other
Acute Lymphocytic Leukemia 13 87% 60 - 69 46 - 54 14 - 15
Acute Myeloid Leukemia 16 83% 84 - 105 68 - 86 15 - 19
Aplastic Anemia 12 88% 52 - 62 39 - 49 13
Cell Therapy 5 91% 59 - 62 46 - 49 12 - 13
Chronic Lymphocytic Leukemia 2 94% 36 - 37 21 - 22 15
Chronic Myeloid Leukemia 11 93% 53 - 58 41 - 46 12
Donor Selection 9 87% 60 - 68 45 - 53 14 - 15
Hodgkin’s Lymphoma 6 90% 68 - 74 50 - 55 17 - 19
Non-Hodgkin's Lymphoma (part 1) 7 94% 63 - 67 47 - 51 16
Non-Hodgkin's Lymphoma (part 2) 7 66% 29 - 38 17 - 23 12 - 15
Multiple Myeloma 25 83% 53 - 76 40 - 61 13 - 15
Myelo- dysplastic/proliferative 
Neoplasms 12 86% 46 - 67 33 - 53 13 - 14
Thalassemia 6 87% 56 - 62 44 - 49 12 - 13
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Figure 1: Meta analyses revealed varying levels of concordance between survey responses, depending on the national 
origin of the respondent (A), general category of question (B), or disease setting/topic (C). A. We plotted the percentage of 
responses by China (x-axis) and “Other” (y-axis) physicians for each answer choice across all survey questions (crosses), and calculated 
a linear best fit (R2, coefficient of determination, black line) as a measure of agreement between the geographic groups. A theoretical 
perfect 1:1 fit is represented by the green line. B. Each question was grouped into one of five general categories (x-axis), and the largest 
overall percent response among the answer choices captured as a proxy for the degree of consensus or unanimity. The average maximum 
response (or degree of consensus) is shown +/- 1 standard deviation. C. Numerous metrics were tabulated to describe the level of similarity 
between the stratified China and “Other” groups within and between each survey module (x-axis). The left vertical axis reports the percent 
of responses. The purple line indicates the percent of answer choices that were ranked in the same order between groups. The blue line 
represents the mean difference in percent response between China and Other for each answer choice, with 95% confidence intervals shaded 
light blue, and the absolute range in percent differences shaded grey. The linear best fit (R2) for each module was calculated as in (A), 
shown in green on the right vertical axis. CLL is an outlier due to only 2 questions, one of which was heavily skewed.
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China. Given the strong response we observed from 
“Other” group, one might predict the market impact this 
drug will have once it passes regulatory muster in China. 
Consider another example from donor selection module 
that asks: “What is your stem cell source of choice 
when donor options are limited?” Chinese respondents 
overwhelmingly chose haplo-identical donor (66%), while 
a majority of the “Other” group (57%) selected cord blood 
donor. Cord blood SCT is a relatively recent technology, 
with certain innovations and improvements just now 
emerging. Does newness of technology explain low 
adoption among Chinese physicians, do the data reflect a 
lack of practice in cord blood banking, or does some other 
barrier prevent this method from gaining prevalence?
We plotted several metrics to visualize overall 
concordance of responses between geographic groups 
for each module (Figure 1c). CLL was obvious outlier, 
but this may be discounted because the module contained 
only two questions, including ibrutinib example 
above. Thus one heavily weighted difference in drug 
availability is responsible for most of variation in CLL 
data. Nevertheless, for each module we calculated 
coefficient of determination (R2 linear best fit) between 
each answer choice for Other versus China (Figure 1c, 
green line). Highest R2 coefficient was observed for 
Hodgkin Lymphoma, ALL, CML and AML modules. 
Since all questions were multiple choice or simple yes/
no, we tabulated percentage of responses that were 
chosen in same order, or rank, for each question. For 
nine modules, over half the responses were selected in 
same rank order (Figure 1c, purple line). Thus for most 
questions, geographic groups prioritized choices in same 
order, though not with same unanimity. We also asked how 
percentage of each geographic group selecting a given 
response varied. On average, we observed a geographic 
difference of 15% for any particular answer choice, and 
this was fairly constant across survey modules (Figure 1c, 
blue line). However, range of differences varied widely 
(Figure 1c, grey fill), suggesting some topics are subject 
to greater absolute disagreement. 
Leukemia
The main trend from this module was an overall 
high level of concordance between physicians from China 
and the other represented countries. In our final analysis 
we observed a coefficient of determination (R2) of 0.67 for 
all responses between these groups, and 68% of answers 
were chosen in the same rank order (Figure 1c). One topic 
of general agreement regarded the relatively new drug 
sorafenib, a tyrosine kinase inhibitor (TKI) that targets 
Fms-like tyrosine kinase 3 (FLT3). Most respondents 
(90% overall) would recommend allogeneic stem cell 
transplant for FLT3+ve AML in light of sorafenib 
availability which remains consistent with the NCCN 
guidelines, and 70% overall would employ sorafenib in 
post-transplant maintenance if FLT3 remains positive. 
However, nearly half of respondents (46%) in both groups 
expressed a similar desire for more data before they would 
adopt sorafenib for AML induction.
In the chronic myeloid leukemia (CML) module, 
we asked about treatment preferences under a series of 
disease conditions: newly diagnosed accelerated phase; 
minor cytogenetic remission after 18 months of imatinib-
based therapy; relapse following imatinib therapy; relapse 
now in 2nd chronic phase; and complete cytogenetic 
response but no molecular response following 18 months 
of imatinib. For newly diagnosed CML, a plurality of all 
physicians preferred imatinib to dasatinib, nilotinib, or 
allo-SCT. Some consider imatinib the “gold standard” for 
first-line CML treatment, though others are wary due to 
a propensity for the development of resistance mutations 
during therapy [3-5]. All such options are also listed in the 
NCCN guidelines and the choice of the tyrosine kinase 
inhibitor (TKI) depends on the practicing physicians. In 
cases of relapse or remission following imatinib therapy, 
dasatinib was the plurality choice (Figure 2a, 2b). These 
drugs are all TKIs targeting the BCR-ABL fusion gene 
product, albeit with varying degrees of specificity and 
efficacy. Additional follow-up questions will be required 
to learn the reasons our respondents preferred one 
TKI over another in the same disease context. A larger 
percentage of the Chinese physicians selected allogenic 
stem cell transplant than did ‘Other’ cohort. This could 
reflect a difference in treatment philosophy, or a difference 
in relative availability/cost of drugs versus cell therapies 
[6].
Molecular testing and genomic profiling of acute 
lymphocytic leukemia (ALL) has featured prominently 
in literature. Physicians aim to determine the nature 
of the bone marrow microenvironment, the B- or 
T-cell lineage of the cancerous cells, and the specific 
mutations driving the neoplasm [7-9]. Consistent with 
these practice patterns, a large majority of physicians in 
our survey report performing molecular testing for ALL 
patients (89% China, 71% Other), and more still base 
their therapy decision on results from molecular testing 
(90% China, 86% Other). The difference in percentage 
between ‘Other’ cohort between these two responses may 
reflect workflows in which physicians do not themselves 
perform/order the testing, but rather see patients whom 
have already been tested. Alternatively, this discrepancy 
might be due to variation intrinsic in our response capture 
methods. Focused genetic testing and molecular screening 
of ALL patients aim to improve risk assessment, targeted 
therapy, and treatment outcomes. With these goals in 
mind, a large majority of survey respondents also perform 
minimal residual disease (MRD) analysis on all of their 
ALL patients (94% China, 71% Other). Therapy for ALL 
typically is dictated by the level of risk/aggressiveness 
of disease, best assessed with sensitive and fast MRD 
detection methods [10]. 
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Figure 2: Physicians report different treatment preferences for acute lymphocytic leukemia (ALL, A) as well as for 
chronic myeloid leukemia (CML, B.). Here we display the results regarding the use of tyrosine kinase inhibitors imatinib, dasatinib 
and nilotinib. Each question is summarized to the left of the graph, with each answer choice immediately adjacent to the y-axis. As indicated 
in the legend above the figure, the percent of overall respondents (x-axis) that selected a particular answer choice is represented by a black 
bar. China and Other sub-groups are shown as squares and circles, respectively. Each question/answer set is separated by gray shading 
on the chart. Physicians reported treatment preferences for different scenarios regarding Hodgkin lymphoma (HL, C), as well as for non-
Hodgkin lymphoma (NHL, D). C. The use of brentuximab vedotin (BV) varied depending on HL conditions among the two groups of 
respondents. Each question is summarized to the left of the graph, with each answer choice immediately adjacent to the y-axis. As indicated 
in the legend above the figure, the percent of overall respondents (x-axis) that selected a particular answer choice is represented by a black 
bar. China and Other sub-groups are shown as squares and circles, respectively. Each question/answer set is separated by gray shading on 
the chart. D. The China and Other groups’ intent to use ibrutinib varied between mantle cell and large cell lymphoma. Each question is 
provided to the left of the chart. The percent of physicians responding “Yes” (x-axis) is shown to the left of the vertical axis, while the “No” 
responses are shown to the right. Responses belonging to the geographic groups are labeled accordingly. E. Physicians from China were 
more likely to select stem cell transplant (SCT) from the multiple answer choices than were physicians in the Other group. The percent of 
respondents selecting each SCT answer choice are plotted with China on the y-axis and Other on the X-axis. The dotted line represents a 
1:1 correspondence. The solid line represents the linear best-fit of the data, which is shifted upwards about 15 percentage points.
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The survey included just two questions on Chronic 
Lymphocytic Leukemia (CLL). When asked about the 
treatment of choice for relapsed/refractory CLL, a majority 
of Chinese physicians selected bendamustine, an alkylating 
agent applied widely for CLL and other lymphomas. 
Meanwhile, a majority of non-Chinese respondents 
selected ibrutinib, a targeted inhibitor of Bruton’s tyrosine 
kinase [11]. Ibrutinib is a cutting edge treatment gaining 
favor in the West and around the world, but at the time 
of the survey had not yet achieved regulatory approval in 
China. This simple difference in drug availability caused 
our CLL survey module to stand apart as an outlier in the 
above meta-analysis. Nevertheless, we believe these kinds 
of data are important for predicting the clinical penetration 
new pharmaceuticals may have upon regulatory approval 
and market availability.
Lymphoma
The Hodgkin lymphoma (HL) module saw 
relatively high accord between Chinese and Other 
respondents (Figure 1c), though overall responses to 
any given question often varied widely (Figure 2c). For 
example, when asked whether one would recommend 
upfront treatment with brentuximab vedotin (BV) for 
Hodgkin lymphoma, 46% responded “yes” with 54% 
“no.” BV is approved in USA for patients in relapse 
following high-dose therapy, stem cell rescue, or multiple 
rounds of chemotherapy, but usually is not considered for 
upfront therapy [12, 13]. However, a recent phase II study, 
published after our survey was collected, demonstrated a 
benefit to front-line BV in older patients who would not 
tolerate typical chemotherapy regimes13. Autologous SCT 
was preferred for relapsed HL among 79% of respondents. 
Overall 68% of respondents offer allogenic SCT in relapse 
following auto-SCT. A majority (63%) do not offer BV 
maintenance therapy, though this too may be challenged 
by new information (Figure 2c). Another recent study 
makes a case for BV as maintenance after auto-SCT in 
high-risk patients [15]. We will be interested to document 
how physician attitudes towards BV therapy change over 
time as these and future clinical data become widely 
known.
Physicians in our survey frequently displayed 
strong agreement in regards to non-Hodgkin lymphomas. 
Answers regarding peripheral T-cell lymphoma, large cell 
lymphoma, salvage therapy, etc., were selected in similar 
proportions and in similar rank order between geographic 
groups. Even when asked ibrutinib, which was not 
available outside of clinical trials in China, respondents 
were consistent in their intent to use for large cell 
lymphoma (but not mantle cell lymphoma) (Figure 2d). 
Several questions did elicit strikingly different opinions 
along geographic lines, however. Whether to offer 
auto-SCT for high risk diffuse large B-cell lymphoma 
(DLBCL), Chinese physicians overwhelmingly said “yes” 
(80%), versus the international group’s 38% “yes.” At this 
time high dose therapy is recommended for relapsed / 
refractory disease based on NCCN guidelines. Preferences 
for mantle cell lymphoma therapy also varied between 
these groups. The largest difference was the simple yes/
no: Do you perform gene expression profiling on your 
patients? 86% of Chinese respondents were affirmative, 
versus 36% of the Others. For more than a decade gene 
microarrays have been used to classify subtypes of NHL, 
and with the eager adoption of next generation sequencing 
around the world, we predict that gene expression profiling 
will become a standard approach to pinpointing cancers 
and refining therapeutic approaches [16-18].
Bone marrow dysfunction
Nearly all respondents in our survey treat del5q 
MDS patients with lenalidomide (95%), offer allo-SCT for 
high risk MDS (97%), and, as mentioned above, analyze 
JAK2 mutation status (97%). Despite a near unanimous 
concern over JAK2, 40% of Chinese respondents do not 
prescribe ruxolitinib, a novel JAK kinase inhibitor recently 
shown to be effective in the JAK positive MDS setting 
[19-21]. Newness of the ruxolitinib data suggest that future 
surveys will reveal a greater awareness and adoption of 
this treatment. A large majority of survey respondents 
(69%) offer induction prior to allo-SCT, most commonly 
with hypomethylating agents (HMA). However, HMA 
of choice varies between Chinese (80% decitabine) 
and Other physicians (85% 5-azacytidine), reflecting a 
difference in drug availability. Clinical studies and meta-
analyses have sought to determine which therapy is most 
effective, concluding that while both HMAs are beneficial, 
5-azacytidine has overall survival advantage [22-24].
Aplastic anemia (AA) module revealed several 
interesting geographic trends in patient composition 
and practice patterns. For instance, a large majority of 
Chinese physicians (88%) routinely use growth factors 
in the treatment of aplastic anemia, versus only 38% of 
the Other counterparts. Growth factors are sometimes 
used in patients who receive immunosuppressive therapy 
in lieu of SCT eligibility. Still, the value and efficacy of 
growth factors has been called into doubt by a number of 
primary studies and meta-analyses [25, 26]. We believe 
this common practice among our Chinese respondents 
reveals a need for updated, evidence-based protocols in 
the AA setting. 
Though not every AA question yielded statistically 
different results between groups, we believe that various 
trends are worth additional attention in future studies. For 
example, when asked what criteria are used to determine 
transplant eligibility, most Chinese physicians selected all 
four choices: disease severity (82%), donor availability 
(82%), performance status (74%), and affordability (74%). 
Their international colleagues selected the first three of 
these at similar frequencies, but only 38% of the Others 
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chose affordability as a criteria for transplant eligibility. 
This discrepancy may reflect the relative wealth of the 
patient population, the relative cost of treatment or 
availability of insurance coverage, and/or a more fiscally 
conservative approach to care delivery in the Chinese 
healthcare system. 
Chinese physicians report seeing fewer thalassemia 
patients in general, and fewer high-risk class 3 patients 
in particular, than their international counterparts. 
Nevertheless, a greater percentage of Chinese respondents 
(72% versus 42% Other) offer allo-SCT to these high-
risk patients. This is consistent with a general trend in 
the data across various cancer settings, whereby Chinese 
physicians are more likely to recommend allo-SCT, or 
to rank this treatment highly among the various options 
(Figure 2e).
The multiple myeloma (MM) module, by far the 
largest question set in our survey, has been recently 
published by Lu et al., [2] and thus we will not go into 
detail. Major take-away from the MM analysis is that 
Chinese physicians are eager to gain regulatory approval 
for new breakthrough therapies such as carfilzomib and 
elotuzumab, which have been shown to improve PFS after 
years of stagnation in treatment outcomes in this setting 
[27-29]. 
Cell therapy
A majority of Chinese respondents (69%) perform 
cell therapy at their centers, versus 38% of Other 
physicians in the survey. Further, 96% of Chinese 
respondents perform post-transplant donor lymphocyte 
infusions in some scenarios, versus 69% of Others. When 
donor options are limited, 66% of Chinese respondents 
prefer a haplo-identical donor, while 57% of Other 
physicians recommend using cord blood. Cord blood as a 
stem cell source has emerged over the last half decade as 
a promising and effective alternative, but this technology 
clearly has not become a mainstay of the Chinese approach 
to transplantation [30]. Perhaps further research and 
advances in cell expansion, bone marrow targeting and 
GVHD minimization will lead to wider adoption of cord 
blood transplantation [31, 32]. Meanwhile, we observed 
similar patterns between both groups regarding CAR-T 
and NK cell therapy—a majority of physicians overall do 
not use either approach. Most Chinese respondents (71%), 
however, expressed optimism that CAR-T therapy will 
become routine in treating leukemia. Indeed, improving 
CAR-T efficacy and specificity is a major thrust of cancer 
immunotherapy research, with recent advances providing 
reason to be hopeful [33-35]. 
CONCLUSIONS
Recognizing questions or entire disease settings 
in which answers vary between nations, or vary among 
physicians regardless of nationality, begins to address 
an age-old problem: How do we know what we do not 
know? This survey takes a big step towards illuminating 
gaps in access to or availability of therapeutic agents. 
These results reveal a utility and need for widespread 
and ongoing initiatives to assess knowledge and provide 
evidence-based education in real time. The entire global 
community of hematology-oncologists stands to benefit 
from contributing to a broad knowledge base. Data will be 
made all the more valuable by longitudinal participation, 
such that we can monitor changes in the state of the art 
over time.
By sharing our expertise, but also keeping an open 
mind to learn from those more expert than ourselves, we 
all stand to improve as physicians. And in doing so, the 
real winners will be patients, and that is why we practice 
in the first place. 
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